医学新知2026，Vol.36Issue(4)：428-437,中插9-中插11,13.DOI:10.12173/j.issn.1004-5511.202506178
1990-2021年全球与中国老年人群代谢功能障碍相关脂肪性肝病的疾病负担分析
Disease burden of metabolic dysfunction-associated steatotic liver disease in the elderly population globally and in China from 1990 to 2021
摘要
Abstract
Objective To analyze the changing trend and influencing factors of the disease burden of older adults with metabolic dysfunction-associated steatotic liver disease(MASLD)globally and in China from 1990 to 2021,and to predict its future trend.Methods Data on the prevalence and disability-adjusted life years(DALYs)of MASLD among individuals aged 60 years and older from the Global Burden of Disease(GBD)2021 database were extracted for a global context,China,and five socio-demographic index(SDI)regions.Joinpoint regression analysis was employed to calculate the average annual percent change(AAPC)in the age-standardized prevalence(ASPR)and DALY rates(ASDR)from 1990 to 2021,and the subgroup analyses were conducted by age and gender.A three-factor decomposition model was used to quantify the relative impacts of aging,population growth,and epidemiological change on the changes in disease burden,while a Bayesian age-period-cohort model was applied to predict the trend in disease burden of older adults with MASLD from 2022 to 2035.Results The number of MASLD patients in the global and Chinese elderly populations was 366,398,400 cases and 98,916,800 cases in 2021,respectively,representing an increase of 176.40%and 230.71%compared to 1990.The number of DALYs was 1,834,700 person-years and 234,100 person-years,showing increases of 139.52%and 127.06%,respectively.During the period from 1990 to 2021,ASPR[AAPC=0.67%,95%CI(0.62%,0.72%)]and ASDR[AAPC=0.20%,95%CI(0.06%,0.34%)]of MASLD in the global elderly population exhibited a significant upward trend.ASPR[AAPC=0.65%,95%CI(0.55%,0.75%)]of MASLD in the elderly population in China showed a significantly upward trend,while ASDR[AAPC=-0.49%,95%CI(-0.92%,-0.06%)]showed a significantly downward trend.Subgroup analyses by gender indicated that in both 1990 and 2021,the number of prevalence and DALYs in the elderly female populations were higher than those in the corresponding male populations globally and in China.Additionally,while the ASDR of MASLD among the elderly in high-middle and low SDI regions regions showed significant downward trends from 1990 to 2021,the number of patients and DALYs across the five SDI regions increased in 2021 compared to 1990.The 60～64 age group accounted for the highest proportion of case numbers and DALYs among the global elderly population with MASLD in 2021,whereas the 65～69 age group ranked the first in China.Decomposition analysis revealed that population growth was the primary influencing factor for the increase in disease burden of MASLD across all areas,contributing the most(122.09%)to the increase in DALYs in China.The prediction model indicated that by 2035,the number of cases and DALYs in the global elderly population would increase by 65.80%and 43.11%,respectively,compared to 2021,while in China,the increases would be 104.95%and 24.78%,respectively.Conclusion The disease burden of MASLD in the elderly populations globally and in China remains substantial and is expected to continue increasing in the future.It is recommended to promote healthy lifestyle practices while actively adopting a multidisciplinary management approach for elderly MASLD patients and enhancing the research and development of effective drugs to alleviate the burden associated with this disease.关键词
代谢功能障碍相关脂肪性肝病/非酒精性脂肪性肝病/老年人/疾病负担/预测模型Key words
Metabolic dysfunction-associated steatotic liver disease/Non-alcoholic fatty liver disease/Older adult/Disease burden/Prediction model分类
医药卫生引用本文复制引用
张强,陈政涛,丁韵涵,柯立鑫,李洁韵,荀杨芹,卢存存,赵晓晓,王海博,徐鹏,王雅星,赵信科,刘璠,李嘉丽,何涛..1990-2021年全球与中国老年人群代谢功能障碍相关脂肪性肝病的疾病负担分析[J].医学新知,2026,36(4):428-437,中插9-中插11,13.基金项目
河南省中医药科学研究专项课题(2024ZY2046) （2024ZY2046）
河南省科技研发计划联合基金(优势学科培育类)项目(242301420112) （优势学科培育类）
